Modest improvement in overall survival for patients with metastatic pancreatic cancer: A trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008

Pancreas

Volumn 42, Issue 7, 2013, Pages 1157-1163

  Worni, Mathias ^a,b   Guller, Ulrich ^b,c   White, Rebekah R ^a   Castleberry, Anthony W ^a   Pietrobon, Ricardo ^a   Cerny, Thomas ^c   Gloor, Beat ^b   Koeberle, Dieter ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

adenocarcinoma; metastasis; pancreatic cancer; SEER; survival

Indexed keywords

AFRICAN AMERICAN; AGED; ARTICLE; ASIAN; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIED PERSON; OVERALL SURVIVAL; PACIFIC ISLANDER; PANCREAS ADENOCARCINOMA; PANCREAS METASTASIS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; AGED; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROPORTIONAL HAZARDS MODELS; SEER PROGRAM; TIME FACTORS; UNITED STATES;

EID: 84885174025     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e318291fbc5     Document Type: Article

References (40)

1. Gong Z, Holly EA, Bracci PM. Survival in population-based pancreatic cancer patients: San Francisco Bay Area, 1995-1999. Am J Epidemiol. 2011;174:1373-1381.
2. Hariharan D, Saied A, Kocher HM. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford). 2008;10:58-62. (Pubitemid 351298114)
3. Mayo SC, Nathan H, Cameron JL, et al. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer. 2012;118:2674-2681.
4. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210. (Pubitemid 38339364)
5. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277. (Pubitemid 46143304)
6. Cress RD, Yin D, Clarke L, et al. Survival among patients with adenocarcinoma of the pancreas: a population-based study (United States). Cancer Causes Control. 2006;17:403-409.
7. Zell JA, Rhee JM, Ziogas A, et al. Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epidemiol Biomarkers Prev. 2007;16:546-552. (Pubitemid 46548659)
8. Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol. 2007;14:1320-1326. (Pubitemid 46536816)
9. Di Marco M, Di Cicilia R, Macchini M, et al. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? [review]. Oncol Rep. 2010;23:1183-1192.
10. Park JK, Yoon YB, Kim YT, et al. Survival and prognostic factors of unresectable pancreatic cancer. J Clin Gastroenterol. 2008;42:86-91.
11. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806-1813.
12. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer. 2002;94:902-910. (Pubitemid 34150843)
13. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946-3952. (Pubitemid 46630743)
14. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509-3516.
15. Hunter KU, Feng FY, Griffith KA, et al. Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2012;83(3):921-926.
16. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.
17. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413. (Pubitemid 27251144)
18. SEER. National Cancer Institute, Surveillance Epidemiology and End Results. Available at: http://seer.cancer.gov/. Accessed July 15, 2012.
19. Motulsky H. GraphPad Software. Available at: http://www.graphpad.com/ welcome.htm. Accessed July 15, 2012.
20. Schwarz G. Estimating the dimension of a model. Ann Stat. 1978;6:461-464.
21. Park HS, Gross CP, Makarov DV, et al. Immortal time bias: a frequently unrecognized threat to validity in the evaluation of postoperative radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(5):1365-1373.
22. Heinemann V, Boeck S, Hinke A, et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 2008;8:82.
23. Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593-600. (Pubitemid 26285639)
24. Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-Study Group. Eur J Cancer. 2011;47:1676-1681.
25. Scheithauer W, Schull B, Ulrich-Pur H, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol. 2003;14:97-104. (Pubitemid 36150266)
26. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966. (Pubitemid 46972777)
27. Goncalves A, Gilabert M, Francois E, et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol. 2012;23:2799-2805.
28. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622.
29. Kindler HL, Ioka T, Richel DJ, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011;12:256-262.
30. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology GroupYdirected intergroup trial S0205. J Clin Oncol. 2010;28:3605-3610.
31. Mallinson CN, Rake MO, Cocking JB, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J. 1980;281:1589-1591. (Pubitemid 11253138)
32. NCI. National Cancer Institute (NCI), FDA Approval for Gemcitabine Hydrochloride. Available at: http://www.cancer.gov/cancertopics/druginfo/fda- gemcitabine-hydrochloride#Anchor-PanCan. Accessed July 15, 2012.
33. Saif MW. Palliative care of pancreatic cancer. Highlights from the ''2011 ASCO Annual Meeting''; Chicago, IL; June 3-7, 2011. J Pancreas. 2011;12:355-357.
34. Fazal S, Saif MW. Supportive and palliative care of pancreatic cancer. J Pancreas. 2007;8:240-253. (Pubitemid 46522756)
35. Artifon EL, Sakai P, Cunha JE, et al. Surgery or endoscopy for palliation of biliary obstruction due to metastatic pancreatic cancer. Am J Gastroenterol. 2006;101:2031-2037. (Pubitemid 44337628)
36. Lau MK, Davila JA, Shaib YH. Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas. 2010;39:458-462.
37. Baine M, Sahak F, Lin C, et al. Marital status and survival in pancreatic cancer patients: a SEER based analysis. PLoS One. 2011;6:e21052.
38. Osborne C, Ostir GV, Du X, et al. The influence of marital status on the stage at diagnosis, treatment, and survival of older women with breast cancer. Breast Cancer Res Treat. 2005;93:41-47. (Pubitemid 41355989)
39. Kravdal O. The impact of marital status on cancer survival. Soc Sci Med. 2001;52:357-368.
40. Murphy JD, Adusumilli S, Griffith KA, et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007;68:801-808. (Pubitemid 46818734)